|280.17||+3.33||+1.20%||Vol 51.31K||1Y Perf 42.07%|
|Apr 13th, 2021 14:40 DELAYED|
|- -%||- -|
|Target Price||301.25||Analyst Rating||Moderate Buy 1.75|
|Potential %||7.64||Finscreener Ranking||★★+ 47.78|
|Insiders Trans % 3/6/12 mo.||-85/-92/-93||Value Ranking||★+ 44.44|
|Insiders Value % 3/6/12 mo.||-53/-73/-86||Growth Ranking||★★★★+ 66.31|
|Insiders Shares Cnt. % 3/6/12 mo.||-49/-71/-85||Income Ranking||— -|
|Market Cap||9.20B||Earnings Rating||Sell|
|Price Range Ratio 52W %||71.85||Earnings Date||5th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2021|
|Estimated EPS Next Report||1.43|
|EPS Growth Next 5 Years %||14.80|
|Avg. Weekly Volume||167.63K|
|Avg. Monthly Volume||230.85K|
|Avg. Quarterly Volume||205.64K|
Amedisys Inc (NASDAQ: AMED) stock closed at 276.84 per share at the end of the most recent trading day (a -2.21% change compared to the prior day closing price) with a volume of 149.30K shares and market capitalization of 9.20B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 21000 people. Amedisys Inc CEO is Paul B. Kusserow.
The one-year performance of Amedisys Inc stock is 42.07%, while year-to-date (YTD) performance is -5.62%. AMED stock has a five-year performance of 480.38%. Its 52-week range is between 165.42 and 325.12, which gives AMED stock a 52-week price range ratio of 71.85%
Amedisys Inc currently has a PE ratio of 49.60, a price-to-book (PB) ratio of 11.10, a price-to-sale (PS) ratio of 5.76, a price to cashflow ratio of 31.50, a PEG ratio of 2.32, a ROA of 12.48%, a ROC of 16.90% and a ROE of 24.38%. The company’s profit margin is 9.80%, its EBITDA margin is 14.00%, and its revenue ttm is $1.58 Billion , which makes it $48.09 revenue per share.
Of the last four earnings reports from Amedisys Inc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.43 for the next earnings report. Amedisys Inc’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for Amedisys Inc is Moderate Buy (1.75), with a target price of $301.25, which is +7.64% compared to the current price. The earnings rating for Amedisys Inc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amedisys Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Amedisys Inc has a Buy technical analysis rating based on Technical Indicators (ADX : 20.06, ATR14 : 12.51, CCI20 : 203.88, Chaikin Money Flow : -0.02, MACD : -10.95, Money Flow Index : 57.41, ROC : 1.00, RSI : 35.91, STOCH (14,3) : 70.02, STOCH RSI : 0.83, UO : 52.80, Williams %R : -29.98), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amedisys Inc in the last 12-months were: Bruce D. Perkins (Buy at a value of $929 296), Christopher Gerard (Option Excercise at a value of $0), Christopher Gerard (Sold 7 300 shares of value $1 714 599 ), David Kemmerly (Option Excercise at a value of $641 002), David Kemmerly (Sold 25 646 shares of value $4 499 552 ), Denise M. Bohnert (Option Excercise at a value of $37 403), Denise M. Bohnert (Sold 1 538 shares of value $436 561 ), Michael North (Option Excercise at a value of $0), Michael North (Sold 4 069 shares of value $935 870 ), Paul B. Kusserow (Option Excercise at a value of $6 695 000), Scott G. Ginn (Option Excercise at a value of $352 815), Scott G. Ginn (Sold 12 900 shares of value $2 559 067 ), Sharon Brunecz (Option Excercise at a value of $818 900), Sharon Brunecz (Sold 10 218 shares of value $2 324 525 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.